Nathan J. Robison from Mark Kieran’s group in Boston just published a report of a phase II 5 drug regimen built upon the pioneer "4 drug regimen" published 8 years ago. The article is entitled "A phase II trial of a multi-agent oral anti-angiogenic (metronomic) regimen in children with recurrent or progressive cancer" was designed to evaluate the efficacy of a “5-drug” oral regimen in children with recurrent or progressive cancer. One hundred one patients, ≤21 years old with recurrent or (...)